Figure 1 Patients (%) achieving an Assessment in Ankylosing Spondylitis 20 response at week 12 in the etanercept‐treatment groups and the demonstration of non‐inferiority of etanercept 50 mg once weekly (QW) to etanercept 25 mg twice weekly (BIW; modified intent‐to‐treat population; last‐observation‐carried‐forward approach).